Abpro (ABP) Stock Price, News & Analysis

Company Overview

Abpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.

Key Stats

• Today's Range: $0.18 to $0.20
• 50-Day Range: $0.20 to $0.55
• 52-Week Range: $0.18 to $13.00
• Volume: 429,069 shs
• Average Volume: 229,384 shs
• Market Capitalization: $10.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

ABP Stock Analysis - Frequently Asked Questions

How have ABP shares performed this year?

Abpro's stock was trading at $1.79 on January 1st, 2025. Since then, ABP stock has decreased by 88.8% and is now trading at $0.20.
View the best growth stocks for 2025 here.

When did Abpro IPO?

Abpro (ABP) raised $60 million in an IPO on Friday, May 11th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Nomura and Oppenheimer were co-managers.

How do I buy shares of Abpro?

Shares of ABP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Holding & other investment offices
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABP
• CIK: 1893219
• Web: www.atlanticcoastalacquisition.com
• Phone: 248-890-7200
• Fax: N/A
• Employees: 15
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.00
• High Stock Price Target: $4.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +1,900.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $183,000.00
• Price / Sales: 57.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 52,219,000
• Free Float: 4,565,000
• Market Cap: $10.44 million
• Optionable: N/A
• Beta: -0.01